Benjamin F. Edwards & Company Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 101,886 shares of the company’s stock after purchasing an additional 2,159 shares during the period. Johnson & Johnson accounts for about 0.8% of Benjamin F. Edwards & Company Inc.’s holdings, making the stock its 20th biggest holding. Benjamin F. Edwards & Company Inc.’s holdings in Johnson & Johnson were worth $17,998,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently added to or reduced their stakes in the business. Glassy Mountain Advisors Inc. acquired a new position in Johnson & Johnson in the fourth quarter worth about $35,000. Retirement Financial Solutions LLC acquired a new position in Johnson & Johnson in the fourth quarter worth about $40,000. TD Capital Management LLC bought a new position in Johnson & Johnson in the third quarter worth about $48,000. VitalStone Financial LLC bought a new position in Johnson & Johnson in the fourth quarter worth about $52,000. Finally, Iron Horse Wealth Management LLC lifted its holdings in Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after acquiring an additional 159 shares during the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. Credit Suisse Group lifted their price target on Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. UBS Group initiated coverage on Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. SVB Leerink dropped their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Morgan Stanley boosted their target price on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.
Insider Activity
Johnson & Johnson Trading Down 0.8 %
NYSE JNJ opened at $161.05 on Wednesday. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a market cap of $418.53 billion, a price-to-earnings ratio of 33.69, a PEG ratio of 2.78 and a beta of 0.53. The firm’s 50 day moving average price is $158.62 and its two-hundred day moving average price is $166.91.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. During the same period in the previous year, the company posted $2.67 EPS. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 2.96%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s payout ratio is currently 94.56%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
